Clinical Trial Update: Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC [Phase 2]

View source ↗

Summary

A Phase II trial evaluating the combination of camrelizumab and stereotactic body radiotherapy (SBRT) as first-line treatment for recurrent/metastatic head and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• SBRT (stereotactic body radiotherapy)

Snippet

Sponsor: Xingchen Peng | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN